glp 1 risk GLP-1RA Essentials in Gastroenterology: Side Effect Management, Precautions for Endoscopy and Applications for Gastrointestinal Disease Treatment The "Hidden" Risk of GLP-1s

GLP-1 receptor agonists enhance glucose-dependent insulin secretion from pancreatic beta cells while suppressing inappropriate glucagon release, thereby improving glycemic control

PlexusDx offers oral tirzepatide starting at $279/month, which may produce different absorption patterns and side-effect profiles compared to injections

Patients considering GLP-1 medications often start by discussing weight loss goals, medical history, and previous diet or exercise efforts with a clinician

doi: 10.1002/iub.2031

Although these agents produce substantial and sustained weight reduction, emerging clinical observations suggest that chronic therapy may be accompanied by changes in lean mass trajectory, reduced protein intake, and micronutrient insufficiency

Common reasons someone may not be eligible include: Personal or family history of medullary thyroid cancer (MTC) or MEN2 History of serious allergic reaction to the medication Certain pregnancy or breastfeeding situations (your clinician will advise) Specific GI conditions or prior pancreatitis may require extra caution GLP-1 dosing usually starts low and increases gradually to help your body adjust and reduce side effects